BioCentury | Feb 14, 2020
Finance

You say you want a Revolution? Oncology company is latest to post big gain after IPO

Revolution’s first day performance suggests appetite for new biotech listings continues unabated in 2020, as investors’ demand for the cancer company’s shares rose both before and after its offering priced. Revolution Medicines Inc. (NASDAQ:RVMD) raised...
BC Extra | Jan 23, 2020
Financial News

Jan. 22 Financial Quick Takes: Genmab-J&J, Adaptimmune, Revolution, PDC*line

Final sales milestone for Darzalex awards Genmab $150M under J&J deal  Genmab A/S (CSE:GMAB; NASDAQ:GMAB) will receive $150 million from the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) after 2019 sales of multiple...
BioCentury | Jan 9, 2020
Product Development

Pfizer dips into translational regulation for cancer with eFFECTOR deal

eFFECTOR’s deal with Pfizer is the latest indication that translational control elements are a promising, emerging source of new drug targets. The companies teamed up to develop small molecule inhibitors of the translation initiation complex...
BC Innovations | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

The handoff of innovation to academia is all but complete, with universities and other academic institutions accounting for the origin of about 75% of new companies formed in the last three years. But while pharma...
BC Extra | Nov 15, 2019
Clinical News

resTORbio drops respiratory infection program as it looks ahead to Parkinson’s readout

reSTORbio discontinued development of RTB101 to prevent respiratory tract infections after it failed the pivotal PROTECTOR 1 trial, but the company is moving forward with the mTORC1 inhibitor in Parkinson’s disease and other age-related indications....
BC Extra | Nov 7, 2019
Financial News

Nov. 6 Financial Quick Takes: NEA backs Shape's series A; plus Royalty-Eisai-Epizyme, Sinomed, Genecast and Cadence

Shape raises $35.5M A round  RNA editing company Shape Therapeutics Inc. raised $35.5 million in a series A round led by New Enterprise Associates, with participation from CureDuchenne Ventures. The company uses guide RNAs to...
BC Innovations | Oct 29, 2019
Distillery Therapeutics

Combined inhibition of G12C-mutant KRAS, mTOR and IGF1R for NSCLC

DISEASE CATEGORY: Cancer INDICATION: Non-small cell lung cancer (NSCLC) Triple therapy with KRAS-G12C, mTOR and IGF1R inhibitors could treat KRAS G12C-mutant NSCLC. Whole genome screening of an shRNA library for targets whose inhibition enhanced the...
BC Extra | Oct 24, 2019
Preclinical News

Oct. 24 Preclinical Quick Takes: anti-neuraminidase human antibodies for broad flu protection; plus Ionis-Baylor, Merck and more

Broad influenza protection by human antibodies against neuraminidase  A Science study from Scripps Research Institute, Icahn School of Medicine at Mount Sinai and Washington University in St. Louis identified three human antibodies that could serve...
BioCentury | Oct 4, 2019
Finance

Selectivity sets off $37M series A for mTOR company Aeovian

Preclinical selectivity data for Aeovian’s mTORC1 inhibitor prompted venBio and Sofinnova Investments to co-lead the biotech’s $37 million series A after long eyeing the space. “mTORC1 selective inhibition has been a Holy Grail target in...
BioCentury | Sep 14, 2019
Product Development

Success in lung cancer niches will hinge on access to next-gen sequencing

New targeted lung cancer therapies against RET, KRAS and c-MET are all outperforming standard of care in the clinic, including checkpoint inhibitors. But whether these therapies see uptake will likely depend more on whether next-generation...
Items per page:
1 - 10 of 734